查看完整行情页>>

|

货币单位:美元(USD)

Beacon Therapeutics (USA), Inc. (agtc)

实时(?):
盘后(?):
读取中...
  • -- (--%)
开盘价:-- 最高价:-- 最低价:-- 52周最高价:-- 52周最低价:--
成交量:-- 平均成交量:-- 市值:-- 市盈率:-- 预期市盈率:--
每股收益:-- 贝塔系数:-- 股息:-- 收益率:-- 总股本:--
David Jacobs David Jacobs currently works at Beacon Therapeutics (USA), Inc., as Senior VP-Clinical Research & Medical Affairs from 2022.
Matthew Feinsod Matthew Feinsod was the founder of Imagen Biotech, Inc. since 2011, holding the title of Chief Medical Officer. Current jobs include Director at World Eye Mission, Executive VP-Global Strategy & Development at Beacon Therapeutics (USA), Inc. since 2019, and Chief Medical Officer at Kalaris Therapeutics, Inc. starting in 2025. Former jobs include Senior VP-Strategy & Product Development at Oldtech, Inc., Member-Institutional Review Board at The George Washington University Hospital, and Medical Officer at US Food & Drug Administration. Education includes a doctorate from George Washington University and an undergraduate degree from The Wharton School of the University of Pennsylvania.
Abraham Scaria Abraham Scaria is currently the Chief Scientific Officer at Beacon Therapeutics (USA), Inc. He previously worked as the Senior Scientific Director-Gene Therapy at Genzyme Corp., Chief Scientific Officer at IVERIC bio, Inc., Head-Gene Therapy Research at Sanofi Corp., and Vice President & Head-Ophthalmology at Casebia Therapeutics LLC. Scaria received a graduate degree from the University of Mumbai and a doctorate degree from The Indiana University School of Medicine.
David A. Fellows Mr. David A. Fellows is a President at Beacon Therapeutics (USA), Inc., a Chairman at Terns Pharmaceuticals, Inc. and a Chairman at Oxular Ltd. He is on the Board of Directors at Gyroscope Therapeutics Ltd., Jaguar Gene Therapy LLC, Glaucoma Foundation, Arctos Medical and Jaguar Therapeutics. Mr. Fellows was previously employed as a Non-Executive Director by Gyroscope Therapeutics Holdings Plc, a Chief Executive Officer & Director by Nightstar Therapeutics Ltd., a Vice President by Johnson & Johnson Vision Care, Inc., a Managing Director by Allergan Ltd., and a Vice President by Allergan, Inc. He also served on the board at Axovia Therapeutics, Inc. and NightstaRx Ltd. He received his undergraduate degree from Butler University.
Stephen W. Potter Stephen W. Potter currently works at Beacon Therapeutics (USA), Inc., as Chief Business Officer & Vice President from 2015. Mr. Potter also formerly worked at Osiris Therapeutics, Inc., as SVP-Operations & Corporate Development from 2011 to 2012, Genzyme Corp., as Senior VP-Corporate & Business Development from 2006 to 2010, NeoStem, Inc., as Executive Vice President from 2013 to 2015, and Caladrius Biosciences, Inc., as Executive Vice President from 2013 to 2015. Mr. Potter received his undergraduate degree in 1979 from the University of Massachusetts and Masters Business Admin degree from Harvard Business School.
Arnold Lewis Oronsky Arnold Lewis Oronsky's current job(s) include being the Chairman at EpicentRx, Inc., a Director at Kanisa Pharmaceuticals, Inc., a Director at Drais Pharmaceuticals Inc., a Director at Tesaro, Inc., a Director at Centrexion Therapeutics Corp., a Director at Potenza Therapeutics, Inc., a Director at Integrated Diagnostics, Inc., a Director at KalVista Pharmaceuticals Ltd., and a Director at Prothex Pharmaceuticals, Inc.Dr. Oronsky's former job(s) include being the Chairman at Dynavax Technologies Corp. from 2006 to 2020,. a Director at BioTransplant, Inc., a Director at Corixa Corp., a Director at Anesiva, Inc. from 2005 to 2010, a Director at Gilead Colorado, Inc., a Director at Metabasis Therapeutics, Inc. from 2000 to 2010, a Director at Aspreva Pharmaceuticals Corp., a Director at Diatos SA, a Director at AkaRx, Inc., a Director at Amplimmune, Inc., a Director at USDS, Inc., an Independent Director at MacroGenics, Inc. from 2000 to 2014, a Director at AlgoRx Pharmaceuticals, Inc. from 2001 to 2005, an Independent Director at Beacon Therapeutics (USA), Inc. from 2003 to 2017, a Director at Sera Prognostics, Inc., a Director at PMV Pharmaceuticals, Inc., a Director at Tizona Therapeutics, Inc., an Independent Director at KalVista Pharmaceuticals, Inc., a Director at Arcion Therapeutics LLC, and a Managing Director at Interwest Venture Management Co. from 1994 to 2020. Dr. Oronsky's education history includes an undergraduate degree from New York University and a doctorate degree from Columbia University College of Physicians & Surgeons.